¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ !(MA5L-  
/t$+Af,}  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© <;$Sa's,LE  
vh1 Ma<cx  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© Pi &fwGL  
&.cGj @1!J  
1.Co-stimulators (or co-stimulating molecules) mJ6t.%' d  
N3XVT{ yo  
2.NK-kB L337/8fh  
2 Ft0C2  
3.Immunoglobulin superfamily C&gOA8nf  
/I`cS%U  
4.antigen-presenting cell (APC) /?.r!Cp  
5@R15q@c6n  
5.death domain K]H"qG.K  
SHXa{-  
6.CCR and CXCR SxLHFN]  
BRo R"#'  
7.Lectin (or mitogen) J[& 7,}  
YobC'c\~9  
8.Clusters of differentiation, CD) zCj*:n  
GDo)6du  
9.B7 family ?vht~5'  
 2#$}yP~  
10.Cytotoxic T lymphocyte, CTL) ySr091Q  
VuO)  
11.IL-15 and IL-15 receptor (IL-15R) Sq?6R}q%  
IxEQh)J X  
12.MHC restriction W{$+mow7S  
tvj'{W  
13.Affinity-chromatography 6bRQL}[  
@ @3)D%h  
14.Cyctosprin A, CsA mTXNHvv  
:nbW.B3GV  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) 0-t4+T  
O'&X aaZV  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© qs8K jG@  
COkLn)+0  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 1CS]~1Yp:  
93Ci$#<y  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ .2(@jx,[  
 (W}i287  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ d'g{K]=tF  
2fL88/'  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© QLpTz"H  
M;RnH##W  
ÃâÒßѧרҵ£º bbPd&7  
um0}`Xq^  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ Med"dHo7  
}~\].I6  
Ïû»¯ÄÚ¿Æ£º B,VSFpPx  
4iPua"8  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ xz+`]Q  
cwW~ *90#  
ѪҺ²¡Ñ§×¨Òµ£º n5,Pq+[  
hk$nlc|$  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÍøÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»